Welcome to Scantox Neuro GmbH
Scantox Neuro GmbH belongs to the Discovery Business Unit of Scantox Group, focusing on preclinical studies in CNS diseases, Rare Diseases and Mental Disorders. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes Scantox the first choice for most CNS drug development needs.
Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease (NPC1), Gaucher Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Frontotemporal Lobar Degeneration (FTLD) and other neurodegenerative and rare diseases.
Scantox is a leading European contract research organization (CRO) offering a comprehensive portfolio of drug discovery, development and CMC/Analytical services to support pharmaceutical, biotech and medical device industries. Scantox is a trusted CRO since 1977, known for experience, agility, reliability, accessibility and highest 3R standards.
Why Choose Us?
- Customer satisfaction is our absolute priority
- Your timeline is our timeline
- Every study is custom-built
- Scientific input to study design and data interpretation
- Extensive experience with virtually all drug targets and treatment types
- Wide range of validated models and techniques for comprehensive compound tests from a single source
- AAALAC International certification ensures the highest quality standards
